894 results on '"Leary, Alexandra"'
Search Results
2. The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research
3. Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer: Alexandra Leary
4. ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer
5. Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
6. Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
7. Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup
8. Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study
9. Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials
10. Uterine adenosarcoma: Clinical significance of histological classification and SNP array analysis
11. Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluid
12. Circulating Tumor DNA from Ascites as an alternative to tumor sampling for genomic profiling in ovarian cancer patients
13. Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation
14. Stratégies thérapeutiques post-chirurgicales actuelles dans les cancers de l’ovaire en première ligne de traitement
15. The need for pragmatic, affordable, and practice-changing real-life clinical trials in oncology
16. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
17. Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry
18. Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2
19. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
20. Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours
21. A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer
22. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts
23. p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial
24. Endometrioid Borderline Ovarian Tumor: Clinical Characteristics, Prognosis, and Managements
25. Consistent data about the predictive factors of the success of interval debulking surgery (CC0-IDS) in patients with advanced ovarian cancers in two large independent datasets.
26. Efficacy of olaparib combined to metronomic cyclophosphamide and metformin in patients with recurrent advanced/metastatic endometrial by molecular subtypes: ENDOLA phase I/II trial.
27. An evaluation of cell-free tumor DNA from 20 mL of peritoneal fluid for homologous recombination deficiency (HRD) testing in newly diagnosed ovarian cancer (OC).
28. Unveiling the unique identity of clear-cell endometrial cancer (CCEC): A comprehensive comparative analysis with ovarian counterpart and other endometrial subtypes.
29. Targeting the CD47/TSP-1 axis: A promising strategy for patients with ovarian cancer (OC) that relapses on PARP inhibitors (PARPi).
30. Phase Ib INEOV neoadjuvant trial of durvalumab +/- tremelimumab with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): Survival outcomes and immune correlates.
31. Clinico-molecular predictors of exceptional response to immune checkpoint inhibitors (ICI) in metastatic cervical cancer (mCC).
32. Exploring the tumor microenvironment (TME) in patients with mismatch repair-deficient (MMRd) endometrial cancer (EC) undergoing immune checkpoint inhibitor (ICI) therapy: Proteomic insights into immune resistance mechanisms.
33. Updates in the Use of Targeted Therapies for Gynecologic Cancers
34. Prediction of recurrence risk in endometrial cancer with multimodal deep learning
35. Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era
36. Clear Cell Borderline Ovarian Tumor: Clinical Characteristics, Prognosis, and Management
37. Safety of direct oral anticoagulants in patients with advanced solid tumors receiving anti-VEGF agents: a retrospective study
38. Tertiary lymphoid structures critical for prognosis in endometrial cancer patients
39. Clinical utility of comprehensive liquid molecular profiling in patients with advanced endometrial cancer.
40. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
41. Désescalade chirurgicale en oncologie gynécologique
42. Traitement médical de première ligne du cancer épithélial de l’ovaire de haut grade: First-line medical treatment of high-grade epithelial ovarian cancer
43. Spatial profiling of ovarian carcinoma and tumor microenvironment evolution under neoadjuvant chemotherapy
44. Correlation between peritoneal cancer index and survival in advanced epithelial ovarian cancer with complete resection
45. Brenner Borderline Ovarian Tumor: A Case Series and Literature Review
46. Overall Survival With Maintenance Olaparib at a 7-Year Follow-up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
47. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
48. Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial
49. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database
50. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.